Meredith J Barad, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Research they published
62 papers · cited 809 times
Published as Meredith J. Barad at Stanford University, Stanford Medicine.
Research identity is not a guarantee of current clinical practice. Same name is not the same person — if this looks like someone else, tell us.
| 2026 | A meta-analysis of pain intensity changes after placebo interventions in facial pain. | PubMed |
| 2026 | Don’t just fill to fill: thoughts on the 2026 match from the Association of Pain Program DirectorsFirst author | Pain Medicine |
| 2026 | Shrinking pipelines and shifting priorities: an analysis of the 2019-2025 pain medicine fellowship matchLast author | Pain Medicine |
| 2026 | Match Program Signaling in Pain Medicine Fellowship Applications: Association with Interview Outcomes and Implications for a Shrinking Applicant Pipeline. | PubMed |
| 2026 | Endoscopic transnasal sphenopalatine ganglion block for chronic craniofacial pain | European Archives of Oto-Rhino-Laryngology |
| 2026 | Debunking myths in facial pain diagnosis for the pain practitioner | Regional Anesthesia & Pain Medicine |
See the 37 most recent papers
| 2025 | Beyond headache: non-cephalic pain, fatigue, and post-traumatic stress symptoms as longitudinal predictors of chronic migraine outcomes | Pain Medicine |
| 2025 | Reaching international consensus on the definition of refractory migraine using the Delphi method | Cephalalgia |
| 2025 | Practice advisory for intravenous management of headache disorders in hospitalized patients: a review of the evidence and consensus recommendations | Regional Anesthesia & Pain Medicine |
| 2025 | Chronic pain fellowships and emergency medicine residency: similarities and synergy | Pain Medicine |
| 2024 | Enhancing early career development in pain medicine: the comprehensive role of mentorship | Pain Medicine |
| 2024 | Orofacial PainFirst author | CONTINUUM Lifelong Learning in Neurology |
| 2024 | Current state of the pain medicine match: perspective and an eye to the future | Regional Anesthesia & Pain Medicine |
| 2024 | Long-Term Epidural Patching Outcomes and Predictors of Benefit in Patients With Suspected CSF Leak Nonconforming to ICHD-3 Criteria | Neurology |
| 2024 | Diagnosis and Treatment of Spontaneous Intracranial Hypotension | Neurology Clinical Practice |
| 2024 | Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trialsLast author | Headache The Journal of Head and Face Pain |
| 2024 | The current state of training in pain medicine fellowships: An Association of Pain Program Directors ( APPD ) survey of program directorsLast author | Pain Practice |
| 2023 | Pain Medicine Education in the United StatesLast author | Anesthesiology Clinics |
| 2023 | Psychological Approaches for Migraine Management | Anesthesiology Clinics |
| 2023 | Pain Medicine Milestones 2.0: a step into the future | Pain Medicine |
| 2022 | The Molecular Basis and Pathophysiology of Trigeminal Neuralgia | International Journal of Molecular Sciences |
| 2021 | Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group | Pain Medicine |
| 2021 | Did she have an epidural? The long‐term consequences of postdural puncture headache and the role of unintended dural punctureFirst author | Headache The Journal of Head and Face Pain |
| 2021 | The Pain Medicine Fellowship Telehealth Education Collaborative | Pain Medicine |
| 2021 | Percutaneous Interventional Strategies for Migraine Prevention: A Systematic Review and Practice GuidelineFirst author | Pain Medicine |
| 2021 | Chronic disabling postpartum headache after unintentional dural puncture during epidural anaesthesia: a prospective cohort study | British Journal of Anaesthesia |
| 2021 | Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR studyFirst author | Headache The Journal of Head and Face Pain |
| 2020 | Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures | Headache The Journal of Head and Face Pain |
| 2020 | Diagnosis and management of chronic facial painLast author | BJA Education |
| 2019 | Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread painFirst author | Regional Anesthesia & Pain Medicine |
| 2018 | Correction to: Treatment Strategies for the Opioid-Dependent PatientLast author | Current Pain and Headache Reports |
| 2017 | Treatment Strategies for the Opioid-Dependent PatientLast author | Current Pain and Headache Reports |
| 2017 | Effect of Educating the Primary Care Physician About Headache to Help Reduce “Trivial” Referrals and Improve the Number and Quality of “Substantial” Referrals that Truly Need Subspecialty Headache Medicine CareLast author | Current Treatment Options in Neurology |
| 2013 | Complex Regional Pain Syndrome Is Associated With Structural Abnormalities in Pain-Related Regions of the Human BrainFirst author | Journal of Pain |
| 2011 | Human Response to Unintended Intrathecal Injection of Botulinum Toxin | Pain Medicine |
| 2009 | Serratus muscle stimulation effectively treats notalgia paresthetica caused by long thoracic nerve dysfunction: a case series | Journal of Brachial Plexus and Peripheral Nerve Injury |
| 2001 | Xenopus p63 expression in early ectoderm and neurectoderm | Mechanisms of Development |
Topics: Migraine and Headache Studies · Temporomandibular Joint Disorders · Mental Health Treatment and Access · Anesthesia and Pain Management · Pain Mechanisms and Treatments
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Barad’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A88123 · Current
Licensed to practise in California · since 2004 · expires 2027-11-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$38,343
Medicare paid this office $38,343 for 181 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 111 | $18,470 | $111 |
| New patient visit (60+ min) | 50 | $8,361 | $167 |
| Long return visit (40+ min) | 46 | $7,779 | $156 |
| Short return visit (20+ min) | 16 | $1,628 | $78 |
| Administration of psychological or neuropsychological test, first 30 minutes | 11 | $430 | $39 |
See all 6 services
| Return visit (30+ min) | 111 | $18,470 | $111 |
| New patient visit (60+ min) | 50 | $8,361 | $167 |
| Long return visit (40+ min) | 46 | $7,779 | $156 |
| Short return visit (20+ min) | 16 | $1,628 | $78 |
| Administration of psychological or neuropsychological test, first 30 minutes | 11 | $430 | $39 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 19 | $297 | $15 |
Who their Medicare patients are
181 Original Medicare patients in 2024. Average age 68 · Under 65 27% · Women 74% · Also on Medicaid 23% · Health risk score 1.18. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 55% · Depression 39% · Diabetes 19% · Coronary heart disease 17% · Chronic kidney disease 14% · Cancer 13% · Atrial fibrillation 12% · Stroke 12% · Heart failure 9% · COPD 9%.
The office billed $219,632, Medicare allowed $51,025 and paid $38,343; for 327 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 181 | 327 | 68 | 1.18 | $219,632 | $38,343 |
| 2023 | 179 | 280 | 69 | 1.23 | $198,959 | $25,824 |
| 2022 | 164 | 260 | 68 | 1.19 | $177,131 | $24,494 |
| 2021 | 161 | 287 | 67 | 1.39 | $199,131 | $27,803 |
| 2020 | 151 | 307 | 64 | 1.38 | $156,659 | $23,920 |
| 2019 | 168 | 307 | 64 | 1.21 | $83,363 | $24,252 |
| 2018 | 172 | 317 | 64 | 1.22 | $113,989 | $26,379 |
| 2017 | 157 | 279 | 65 | 1.28 | $107,832 | $22,399 |
| 2016 | 192 | 366 | 65 | 1.29 | $216,348 | $29,121 |
| 2015 | 193 | 340 | 65 | 1.38 | $175,034 | $27,765 |
| 2014 | 189 | 353 | 64 | 1.26 | $184,411 | $29,542 |
| 2013 | 170 | 318 | 61 | 1.49 | $140,502 | $26,249 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 102 | $12,101 | $79 |
| Long return visit (40+ min) | 41 | $5,493 | $125 |
| New patient visit (60+ min) | 37 | $4,919 | $133 |
| Short return visit (20+ min) | 11 | $540 | $45 |
2022: 5 services
| Return visit (30+ min) | 78 | $9,199 | $82 |
| Long return visit (40+ min) | 37 | $4,684 | $127 |
| New patient visit (60+ min) | 28 | $3,698 | $132 |
| Return visit (30+ min) | 18 | $2,266 | $81 |
| Short return visit (20+ min) | 11 | $724 | $56 |
2021: 4 services
| Return visit (30+ min) | 87 | $10,459 | $85 |
| Long return visit (40+ min) | 43 | $5,624 | $120 |
| New patient visit (60+ min) | 27 | $4,090 | $151 |
| Return visit (30+ min) | 18 | $3,064 | $81 |
2020: 6 services
| Return visit (30+ min) | 73 | $7,678 | $65 |
| Long return visit (40+ min) | 29 | $2,903 | $97 |
| New patient visit (60+ min) | 19 | $2,760 | $145 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 15 | $2,448 | $102 |
| Return visit (30+ min) | 20 | $2,195 | $69 |
| Short return visit (20+ min) | 23 | $1,154 | $43 |
2019: 6 services
| Return visit (30+ min) | 78 | $6,817 | $64 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 29 | $3,964 | $94 |
| Long return visit (40+ min) | 36 | $3,624 | $95 |
| New patient visit (60+ min) | 21 | $3,018 | $144 |
| Return visit (30+ min) | 14 | $1,579 | $69 |
| New patient visit (45+ min) | 11 | $1,154 | $105 |
2018: 6 services
| Return visit (30+ min) | 72 | $6,982 | $67 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 32 | $5,272 | $96 |
| New patient visit (60+ min) | 32 | $4,649 | $145 |
| New patient visit (45+ min) | 29 | $3,046 | $105 |
| Long return visit (40+ min) | 26 | $2,655 | $98 |
| Other procedure on nervous system | 11 | $234 | $15 |
2017: 6 services
| Return visit (30+ min) | 68 | $6,814 | $67 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 24 | $4,367 | $102 |
| New patient visit (60+ min) | 31 | $4,122 | $133 |
| New patient visit (45+ min) | 25 | $2,764 | $111 |
| Long return visit (40+ min) | 22 | $2,046 | $93 |
| Other procedure on nervous system | 13 | $516 | $21 |
2016: 7 services
| Return visit (30+ min) | 78 | $6,961 | $64 |
| New patient visit (60+ min) | 35 | $4,724 | $135 |
| New patient visit (45+ min) | 37 | $3,893 | $105 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 18 | $3,630 | $101 |
| Long return visit (40+ min) | 15 | $1,487 | $99 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 21 | $853 | $39 |
| Short return visit (20+ min) | 15 | $746 | $44 |
2015: 8 services
| Return visit (30+ min) | 77 | $7,328 | $67 |
| New patient visit (60+ min) | 44 | $6,122 | $139 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 16 | $2,787 | $107 |
| Other procedure on nervous system | 12 | $2,120 | $118 |
| New patient visit (45+ min) | 15 | $1,734 | $116 |
| Long return visit (40+ min) | 14 | $1,210 | $86 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 19 | $679 | $36 |
| Ultrasonic guidance for needle placement | 14 | $474 | $30 |
2014: 8 services
| New patient visit (60+ min) | 59 | $8,590 | $146 |
| Return visit (30+ min) | 74 | $7,089 | $67 |
| Long return visit (40+ min) | 33 | $3,456 | $99 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 13 | $2,705 | $100 |
| New patient visit (45+ min) | 12 | $1,389 | $116 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 21 | $806 | $38 |
| Short return visit (20+ min) | 14 | $546 | $39 |
| Fluoroscopic guidance for spine or back muscle injection | 13 | $355 | $27 |
2013: 8 services
| New patient visit (60+ min) | 48 | $6,658 | $139 |
| Return visit (30+ min) | 52 | $5,555 | $63 |
| Long return visit (40+ min) | 33 | $3,265 | $93 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 18 | $2,550 | $111 |
| New patient visit (45+ min) | 12 | $1,354 | $113 |
| Short return visit (20+ min) | 20 | $791 | $40 |
| Fluoroscopic guidance for spine or back muscle injection | 12 | $379 | $27 |
| Ultrasonic guidance for needle placement | 11 | $317 | $29 |
Medicaid work
$357 in 2021
Medicaid paid $357 for 12 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $357 |
| 2021 | 12 | 1 | 12 | $357 |
Drugs they prescribed that Part D paid
$207,018
Pharmacies billed $207,018 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (45 of 911) in 2024. A higher opioid share than 9 in 10 peers; the typical neurology clinician is at 0%. Long-acting opioids: 44% of their opioid prescriptions.
704 generic and 207 brand-name prescriptions · $207,018 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Emgality | Migraine | 56 | $42,032 | $751 |
| Qulipta | None | 23 | $28,230 | $1,227 |
| Nurtec Odt | None | 11 | $20,467 | $1,861 |
| Reyvow | None | 19 | $13,846 | $729 |
| Ubrelvy | None | 12 | $13,640 | $1,137 |
See all 27 drugs
| Emgality | Migraine | 56 | $42,032 | $751 |
| Qulipta | None | 23 | $28,230 | $1,227 |
| Nurtec Odt | None | 11 | $20,467 | $1,861 |
| Reyvow | None | 19 | $13,846 | $729 |
| Ubrelvy | None | 12 | $13,640 | $1,137 |
| Ajovy | None | 14 | $12,171 | $869 |
| Aimovig | Migraine | 17 | $12,061 | $709 |
| Ajovy | None | 13 | $9,499 | $731 |
| Pregabalin | None | 69 | $2,497 | $36 |
| Duloxetine | None | 72 | $1,714 | $24 |
| Oxcarbazepine | None | 28 | $922 | $33 |
| Gabapentin | None | 62 | $908 | $15 |
| Divalproex | None | 24 | $868 | $36 |
| Naratriptan | None | 23 | $707 | $31 |
| Rizatriptan | None | 31 | $560 | $18 |
| Venlafaxine Hcl Er | None | 30 | $542 | $18 |
| Sumatriptan | None | 47 | $436 | $9 |
| Ondansetron Odt | None | 12 | $374 | $31 |
| Methadone | None | 11 | $324 | $29 |
| Topiramate | None | 28 | $295 | $11 |
| Nortriptyline | None | 12 | $278 | $23 |
| Oxycodone | None | 13 | $203 | $16 |
| Eletriptan Hbr | None | 14 | $199 | $14 |
| Baclofen | None | 11 | $145 | $13 |
| Amitriptyline | None | 12 | $92 | $8 |
| Butalbital-Acetaminophen-Caffe | None | 12 | $38 | $3 |
| Cyclobenzaprine | None | 11 | $28 | $3 |
Year by year
| 2024 | 911 | 149 | 5% (45) | 23% | $207,018 |
| 2023 | 888 | 139 | 5% (42) | 22% | $225,413 |
| 2022 | 822 | 120 | 4% (33) | 22% | $233,421 |
| 2021 | 739 | 104 | 2% (16) | 19% | $151,522 |
| 2020 | 924 | 110 | 6% (56) | 16% | $153,158 |
| 2019 | 860 | 118 | 5% (46) | 16% | $127,993 |
| 2018 | 742 | 108 | 4% (28) | 6% | $59,598 |
| 2017 | 774 | 141 | 3% (19) | 12% | $70,044 |
| 2016 | 688 | 130 | 5% (34) | 13% | $68,039 |
| 2015 | 555 | 102 | 6% (33) | None | $53,873 |
| 2014 | 581 | 105 | 7% (42) | 17% | $74,322 |
| 2013 | 546 | 96 | 19% (103) | None | $72,017 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Emgality | Migraine | 65 | $49,947 | $768 |
| Nurtec Odt | None | 31 | $48,128 | $1,553 |
| Ubrelvy | None | 17 | $17,233 | $1,014 |
| Aimovig | Migraine | 23 | $17,049 | $741 |
| Reyvow | None | 21 | $16,563 | $789 |
| Sumatriptan | None | 11 | $3,692 | $336 |
| Gabapentin | None | 110 | $2,783 | $25 |
| Pregabalin | None | 21 | $1,989 | $95 |
| Sumatriptan | None | 29 | $1,836 | $63 |
| Divalproex | None | 13 | $1,151 | $89 |
| Naratriptan | None | 23 | $1,088 | $47 |
| Duloxetine | None | 44 | $1,081 | $25 |
| Rizatriptan | None | 41 | $1,066 | $26 |
| Memantine | None | 16 | $1,051 | $66 |
| Acetazolamide | None | 11 | $994 | $90 |
| Oxcarbazepine | None | 18 | $897 | $50 |
| Venlafaxine Hcl Er | None | 39 | $702 | $18 |
| Carbamazepine Er | None | 15 | $582 | $39 |
| Methadone | None | 15 | $582 | $39 |
| Topiramate | None | 32 | $487 | $15 |
| Promethazine | None | 15 | $260 | $17 |
| Diclofenac | None | 16 | $180 | $11 |
| Hydromorphone | None | 12 | $168 | $14 |
| Oxycodone | None | 12 | $134 | $11 |
| Buprenorphine | None | 13 | $132 | $10 |
| Prochlorperazine Maleate | None | 16 | $131 | $8 |
| Ondansetron Odt | None | 13 | $101 | $8 |
| Tizanidine | None | 15 | $97 | $6 |
| Ibuprofen | None | 11 | $36 | $3 |
2022: 25 drugs
| Nurtec Odt | None | 63 | $88,738 | $1,409 |
| Emgality | Migraine | 39 | $31,867 | $817 |
| Reyvow | None | 34 | $24,381 | $717 |
| Ubrelvy | None | 13 | $13,831 | $1,064 |
| Ajovy | None | 14 | $10,039 | $717 |
| Sumatriptan | None | 39 | $4,495 | $115 |
| Sumatriptan | None | 15 | $4,022 | $268 |
| Pregabalin | None | 35 | $3,125 | $89 |
| Gabapentin | None | 71 | $2,273 | $32 |
| Duloxetine | None | 23 | $2,249 | $98 |
| Oxcarbazepine | None | 18 | $1,921 | $107 |
| Naratriptan | None | 19 | $1,628 | $86 |
| Rizatriptan | None | 35 | $1,077 | $31 |
| Memantine | None | 26 | $973 | $37 |
| Levetiracetam | None | 11 | $574 | $52 |
| Nortriptyline | None | 20 | $393 | $20 |
| Topiramate | None | 47 | $351 | $7 |
| Promethazine | None | 15 | $345 | $23 |
| Diclofenac | None | 19 | $265 | $14 |
| Venlafaxine Hcl Er | None | 22 | $244 | $11 |
| Oxycodone | None | 13 | $171 | $13 |
| Buprenorphine | None | 14 | $165 | $12 |
| Baclofen | None | 17 | $164 | $10 |
| Tizanidine | None | 11 | $127 | $12 |
| Ibuprofen | None | 16 | $86 | $5 |
2021: 21 drugs
| Nurtec Odt | None | 31 | $39,010 | $1,258 |
| Ubrelvy | None | 20 | $20,167 | $1,008 |
| Aimovig | Migraine | 19 | $15,157 | $798 |
| Ajovy | None | 16 | $11,103 | $694 |
| Emgality | Migraine | 14 | $9,234 | $660 |
| Ajovy | None | 14 | $9,090 | $649 |
| Reyvow | None | 11 | $7,645 | $695 |
| Pregabalin | None | 67 | $4,624 | $69 |
| Sumatriptan | None | 12 | $2,624 | $219 |
| Gabapentin | None | 64 | $1,547 | $24 |
| Oxcarbazepine | None | 26 | $1,469 | $57 |
| Duloxetine | None | 33 | $1,408 | $43 |
| Nortriptyline | None | 32 | $680 | $21 |
| Promethazine | None | 21 | $601 | $29 |
| Rizatriptan | None | 20 | $598 | $30 |
| Sumatriptan | None | 33 | $532 | $16 |
| Naratriptan | None | 21 | $490 | $23 |
| Memantine | None | 13 | $461 | $35 |
| Topiramate | None | 24 | $299 | $12 |
| Ondansetron Odt | None | 14 | $179 | $13 |
| Lamotrigine | None | 11 | $120 | $11 |
2020: 24 drugs
| Aimovig | Migraine | 44 | $35,424 | $805 |
| Pregabalin | None | 76 | $25,400 | $334 |
| Nurtec Odt | None | 13 | $13,699 | $1,054 |
| Ajovy | None | 14 | $9,009 | $643 |
| Sumatriptan | None | 65 | $6,360 | $98 |
| Frovatriptan | None | 19 | $5,255 | $277 |
| Gabapentin | None | 93 | $1,737 | $19 |
| Duloxetine | None | 27 | $1,520 | $56 |
| Naratriptan | None | 29 | $1,492 | $51 |
| Oxcarbazepine | None | 27 | $1,164 | $43 |
| Rizatriptan | None | 21 | $839 | $40 |
| Candesartan Cilexetil | None | 12 | $825 | $69 |
| Diclofenac | None | 14 | $646 | $46 |
| Topiramate | None | 43 | $582 | $14 |
| Dextroamphetamine-Amphetamine | None | 12 | $526 | $44 |
| Nortriptyline | None | 29 | $475 | $16 |
| Amitriptyline | None | 22 | $324 | $15 |
| Doxepin | None | 12 | $262 | $22 |
| Promethazine | None | 23 | $242 | $11 |
| Divalproex Sodium Er | None | 11 | $203 | $18 |
| Oxycodone | None | 19 | $193 | $10 |
| Paroxetine | None | 15 | $158 | $11 |
| Cyclobenzaprine | None | 13 | $82 | $6 |
| Furosemide | None | 11 | $34 | $3 |
2019: 23 drugs
| Aimovig | Migraine | 53 | $41,687 | $787 |
| Lyrica | None | 24 | $19,447 | $810 |
| Pregabalin | None | 26 | $2,079 | $80 |
| Gabapentin | None | 106 | $1,723 | $16 |
| Oxcarbazepine | None | 41 | $1,549 | $38 |
| Topiramate | None | 56 | $1,321 | $24 |
| Naratriptan | None | 26 | $1,272 | $49 |
| Duloxetine | None | 27 | $1,189 | $44 |
| Sumatriptan | None | 53 | $1,011 | $19 |
| Divalproex | None | 16 | $740 | $46 |
| Nortriptyline | None | 37 | $672 | $18 |
| Memantine | None | 18 | $414 | $23 |
| Rizatriptan | None | 19 | $400 | $21 |
| Promethazine | None | 37 | $355 | $10 |
| Doxepin | None | 12 | $262 | $22 |
| Carbamazepine | None | 16 | $223 | $14 |
| Propranolol | None | 11 | $220 | $20 |
| Verapamil Er | None | 14 | $192 | $14 |
| Diclofenac | None | 14 | $180 | $13 |
| Modafinil | None | 11 | $141 | $13 |
| Oxycodone | None | 16 | $118 | $7 |
| Cyclobenzaprine | None | 11 | $72 | $7 |
| Ondansetron Odt | None | 11 | $69 | $6 |
2018: 22 drugs
| Lyrica | 23 | $19,349 | $841 |
| Gabapentin | 95 | $2,426 | $26 |
| Acetazolamide | 20 | $2,389 | $119 |
| Naratriptan | 40 | $2,087 | $52 |
| Duloxetine | 31 | $1,630 | $53 |
| Oxcarbazepine | 35 | $1,593 | $46 |
| Sumatriptan | 43 | $1,469 | $34 |
| Topiramate | 54 | $1,212 | $22 |
| Tramadol Hcl Er | 13 | $876 | $67 |
| Rizatriptan | 27 | $872 | $32 |
| Verapamil Er | 25 | $736 | $29 |
| Nortriptyline | 35 | $705 | $20 |
| Dextroamphetamine-Amphetamine | 11 | $573 | $52 |
| Tizanidine | 13 | $291 | $22 |
| Memantine | 14 | $259 | $18 |
| Promethazine | 23 | $188 | $8 |
| Cyclobenzaprine | 14 | $170 | $12 |
| Baclofen | 19 | $167 | $9 |
| Diclofenac | 13 | $134 | $10 |
| Carbamazepine | 13 | $119 | $9 |
| Oxycodone | 12 | $99 | $8 |
| Ibu | 12 | $34 | $3 |
2017: 16 drugs
| Lyrica | 34 | $25,805 | $759 |
| Duloxetine | 47 | $3,104 | $66 |
| Gabapentin | 142 | $2,750 | $19 |
| Naratriptan | 38 | $2,539 | $67 |
| Acetazolamide | 20 | $2,122 | $106 |
| Lidocaine | 18 | $1,563 | $87 |
| Sumatriptan | 21 | $1,458 | $69 |
| Rizatriptan | 28 | $1,402 | $50 |
| Indomethacin Er | 11 | $1,125 | $102 |
| Oxcarbazepine | 18 | $838 | $47 |
| Tizanidine | 16 | $580 | $36 |
| Topiramate | 26 | $490 | $19 |
| Nortriptyline | 32 | $361 | $11 |
| Promethazine | 22 | $263 | $12 |
| Levothyroxine | 14 | $198 | $14 |
| Carbamazepine | 12 | $21 | $2 |
2016: 16 drugs
| Lyrica | 47 | $28,543 | $607 |
| Lidocaine | 28 | $5,736 | $205 |
| Acetazolamide | 29 | $4,641 | $160 |
| Gabapentin | 116 | $2,968 | $26 |
| Duloxetine | 20 | $1,985 | $99 |
| Rizatriptan | 38 | $1,289 | $34 |
| Modafinil | 11 | $1,166 | $106 |
| Mexiletine | 11 | $965 | $88 |
| Tizanidine | 12 | $841 | $70 |
| Sumatriptan | 26 | $840 | $32 |
| Promethazine | 11 | $554 | $50 |
| Topiramate | 43 | $441 | $10 |
| Naratriptan | 13 | $378 | $29 |
| Nortriptyline | 26 | $285 | $11 |
| Baclofen | 11 | $233 | $21 |
| Ibuprofen | 13 | $108 | $8 |
2015: 16 drugs
| Lyrica | 25 | $17,383 | $695 |
| Lidocaine | 19 | $5,564 | $293 |
| Duloxetine | 38 | $5,017 | $132 |
| Gabapentin | 79 | $2,570 | $33 |
| Rizatriptan | 18 | $1,027 | $57 |
| Tizanidine | 16 | $836 | $52 |
| Naratriptan | 15 | $692 | $46 |
| Topiramate | 45 | $542 | $12 |
| Baclofen | 16 | $452 | $28 |
| Sumatriptan | 19 | $398 | $21 |
| Venlafaxine Hcl Er | 17 | $263 | $15 |
| Zolpidem | 18 | $208 | $12 |
| Nortriptyline | 14 | $161 | $11 |
| Ibuprofen | 14 | $130 | $9 |
| Metoclopramide | 11 | $79 | $7 |
| Mirtazapine | 12 | $57 | $5 |
2014: 17 drugs
| Lyrica | 31 | $17,181 | $554 |
| Duloxetine | 30 | $12,127 | $404 |
| Nuvigil | 11 | $5,727 | $521 |
| Lidocaine | 33 | $3,219 | $98 |
| Gabapentin | 77 | $2,766 | $36 |
| Sumatriptan | 31 | $2,526 | $81 |
| Diclofenac | 11 | $2,045 | $186 |
| Tizanidine | 19 | $1,819 | $96 |
| Venlafaxine Hcl Er | 19 | $1,061 | $56 |
| Cyclobenzaprine | 18 | $864 | $48 |
| Zonisamide | 13 | $444 | $34 |
| Nortriptyline | 22 | $326 | $15 |
| Topiramate | 22 | $294 | $13 |
| Baclofen | 19 | $282 | $15 |
| Zolpidem | 15 | $117 | $8 |
| Ibuprofen | 11 | $99 | $9 |
| Tramadol | 11 | $87 | $8 |
2013: 14 drugs
| Cymbalta | 44 | $19,275 | $438 |
| Lyrica | 35 | $12,317 | $352 |
| Rizatriptan | 17 | $3,922 | $231 |
| Celebrex | 15 | $3,750 | $250 |
| Gabapentin | 64 | $2,427 | $38 |
| Sumatriptan | 22 | $1,696 | $77 |
| Venlafaxine Hcl Er | 25 | $979 | $39 |
| Zonisamide | 13 | $736 | $57 |
| Topiramate | 15 | $510 | $34 |
| Propranolol | 11 | $414 | $38 |
| Hydrocodone-Acetaminophen | 18 | $253 | $14 |
| Methadone | 24 | $251 | $10 |
| Nortriptyline | 14 | $192 | $14 |
| Zolpidem | 11 | $64 | $6 |
Money from drug and device companies
$375 in 2025
| 2025 | 1 | 1 | $375 | $375 |
| 2024 | 2 | 3 | $875 | $916 |
| 2023 | 2 | 3 | None | $110 |
| 2022 | 4 | 4 | $1,500 | $1,557 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | None | $375 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Consulting · 2025-11-24 | None | $375 |
See earlier years (2024, 2023, 2022)
2024: $916
| Merck Sharp & Dohme | None | $875 | 2 payments
|
| Teva Pharmaceuticals USA | None | $41 | 1 payment
|
2023: $110
| Impel Pharmaceuticals | Trudhesa | $69 | 2 payments
|
| Teva Pharmaceuticals USA | Ajovy | $41 | 1 payment
|
2022: $1,557
| SPR Therapeutics | Sprint Pns System | $1,000 | 1 payment
|
| NeuroMetrix | None | $500 | 1 payment
|
| Impel Pharmaceuticals | Trudhesa | $55 | 1 payment
|
| GRT US Holding | Qutenza | $2 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1568656353
- Licence
- CA A88123California A88123: Current · expires 2027-11-30
- Trained
- Stanford University School of Medicine, 2003
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084P2900X (2084P2900X); Neurology (2084N0400X)
- Mailing address
- Stanford University Medical Center, Pain Management Clinic, 300 Pasteur Dr., Rm A408, Stanford, CA, 94305
- NPI first listed
- 2007-09-05
- NPI last updated
- 2024-04-08
- NPI record certified
- 2024-04-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: Stanford University Medical Center, Stanford, CA, 94305